{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:18:20Z","timestamp":1787667500560,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K08177"],"award-info":[{"award-number":["23K08177"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00535-026-02443-z","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:43:00Z","timestamp":1778769780000},"page":"1269-1283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chemotherapy-induced cell cycle arrest is associated with increased claudin-18 isoform 2 expression and enhanced zolbetuximab-mediated cytotoxicity in gastric cancer"],"prefix":"10.1007","volume":"61","author":[{"given":"Chiaki","family":"Takiguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9339-3792","authenticated-orcid":false,"given":"Shotaro","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Matsuida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Hanayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Matsuishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuharu","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohei","family":"Hayashishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Mitsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motonobu","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Okayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenichiro","family":"Saze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Momma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rei","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"3","key":"2443_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"2443_CR2","volume":"8","author":"AD Wagner","year":"2017","unstructured":"Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8(8):Cd004064.","journal-title":"Cochrane Database Syst Rev"},{"key":"2443_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.705999","volume":"12","author":"DK Wang","year":"2021","unstructured":"Wang DK, Zuo Q, He QY, et al. Targeted immunotherapies in gastrointestinal cancer: from molecular mechanisms to implications. Front Immunol. 2021;12:705999.","journal-title":"Front Immunol"},{"key":"2443_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172725","author":"DM Han","year":"2025","unstructured":"Han DM, Wakefield MR, Fang Y. Beyond detection: conventional and emerging biomarkers in gastrointestinal cancers. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17172725.","journal-title":"Cancers (Basel)"},{"issue":"23","key":"2443_CR5","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14(23):7624\u201334.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2443_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin U, T\u00fcreci \u00d6, Manikhas G, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32(5):609\u201319.","journal-title":"Ann Oncol"},{"issue":"3","key":"2443_CR7","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s10120-020-01153-6","volume":"24","author":"F Lordick","year":"2021","unstructured":"Lordick F, Al-Batran SE, Ganguli A, et al. Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma. Gastric Cancer. 2021;24(3):721\u201330.","journal-title":"Gastric Cancer"},{"issue":"10389","key":"2443_CR8","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655\u201368.","journal-title":"Lancet"},{"issue":"8","key":"2443_CR9","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133\u201341.","journal-title":"Nat Med"},{"issue":"5","key":"2443_CR10","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/path.1922","volume":"208","author":"Y Sanada","year":"2006","unstructured":"Sanada Y, Oue N, Mitani Y, et al. Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype. J Pathol. 2006;208(5):633\u201342.","journal-title":"J Pathol"},{"issue":"1","key":"2443_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-68970-y","volume":"14","author":"A Matsuishi","year":"2024","unstructured":"Matsuishi A, Nakajima S, Saito M, et al. The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancer. Sci Rep. 2024;14(1):17916.","journal-title":"Sci Rep"},{"issue":"3","key":"2443_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jphs.2024.04.004","volume":"155","author":"T Nishibata","year":"2024","unstructured":"Nishibata T, Weng J, Omori K, et al. Effect of anti-Claudin 18.2 monoclonal antibody zolbetuximab alone or combined with chemotherapy or Programmed cell death-1 blockade in syngeneic and xenograft gastric cancer models. J Pharmacol Sci. 2024;155(3):84\u201393.","journal-title":"J Pharmacol Sci"},{"issue":"2","key":"2443_CR13","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1158\/0008-5472.CAN-17-2782","volume":"78","author":"CC Mills","year":"2018","unstructured":"Mills CC, Kolb EA, Sampson VB. Development of chemotherapy with cell-cycle inhibitors for adult and pediatric cancer therapy. Cancer Res. 2018;78(2):320\u20135.","journal-title":"Cancer Res"},{"issue":"1","key":"2443_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-024-02080-z","volume":"10","author":"I Pellarin","year":"2025","unstructured":"Pellarin I, Dall\u2019Acqua A, Favero A, et al. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduct Target Ther. 2025;10(1):11.","journal-title":"Signal Transduct Target Ther"},{"key":"2443_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154699","volume":"248","author":"D Tao","year":"2023","unstructured":"Tao D, Guan B, Li Z, et al. Correlation of Claudin18.2 expression with clinicopathological characteristics and prognosis in gastric cancer. Pathol Res Pract. 2023;248:154699.","journal-title":"Pathol Res Pract"},{"issue":"1","key":"2443_CR16","doi-asserted-by":"publisher","first-page":"19234","DOI":"10.1038\/s41598-025-03924-6","volume":"15","author":"R Kanoda","year":"2025","unstructured":"Kanoda R, Nakajima S, Okayama H, et al. Downregulation of cGAS\/STING expression in tumor cells by cancer-associated fibroblasts in colorectal cancer. Sci Rep. 2025;15(1):19234.","journal-title":"Sci Rep"},{"issue":"2","key":"2443_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7171\/jbt.18-2902-002","volume":"29","author":"A Bairoch","year":"2018","unstructured":"Bairoch A. The cellosaurus, a cell-line knowledge resource. J Biomol Tech. 2018;29(2):25\u201338.","journal-title":"J Biomol Tech"},{"issue":"269","key":"2443_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science Signaling. 2013;6(269):pl1.","journal-title":"Science Signaling"},{"key":"2443_CR19","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00925","volume":"9","author":"A Jubashi","year":"2025","unstructured":"Jubashi A, Nakayama I, Sakamoto N, et al. Prognostic indicators of preoperative fluorouracil, leucovorin, oxaliplatin, and docetaxel efficacy in locally advanced gastroesophageal and gastric cancer: integrating biomarker analysis and clinicopathological factors. JCO Precis Oncol. 2025;9:e2400925.","journal-title":"JCO Precis Oncol"},{"key":"2443_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012683","author":"SH Lim","year":"2025","unstructured":"Lim SH, Kuwata T, An M, et al. Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2025-012683.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2443_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25\u201335.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2443_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andr\u00e9 F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209\u201319.","journal-title":"N Engl J Med"},{"issue":"1","key":"2443_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/1078-0432.CCR-24-0036","volume":"31","author":"MH O'Hara","year":"2025","unstructured":"O\u2019Hara MH, Jegede O, Dickson MA, et al. Phase II study of palbociclib in patients with tumors with CDK4 or CDK6 amplification: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C. Clin Cancer Res. 2025;31(1):56\u201364.","journal-title":"Clin Cancer Res"},{"key":"2443_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02584","volume":"10","author":"D Shinko","year":"2019","unstructured":"Shinko D, McGuire HM, Diakos CI, et al. Mass cytometry reveals a sustained reduction in CD16(+) natural killer cells following chemotherapy in colorectal cancer patients. Front Immunol. 2019;10:2584.","journal-title":"Front Immunol"},{"issue":"1","key":"2443_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","volume":"8","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59\u201373.","journal-title":"Nat Rev Immunol"},{"key":"2443_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51\u201372.","journal-title":"Annu Rev Immunol"},{"issue":"7668","key":"2443_CR27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature23465","volume":"548","author":"S Goel","year":"2017","unstructured":"Goel S, DeCristo MJ, Watt AC, et al. CDK4\/6 inhibition triggers anti-tumour immunity. Nature. 2017;548(7668):471\u20135.","journal-title":"Nature"},{"issue":"2","key":"2443_CR28","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","volume":"8","author":"J Deng","year":"2018","unstructured":"Deng J, Wang ES, Jenkins RW, et al. CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 2018;8(2):216\u201333.","journal-title":"Cancer Discov"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02443-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02443-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02443-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:18:39Z","timestamp":1787663919000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-026-02443-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2443"],"URL":"https:\/\/doi.org\/10.1007\/s00535-026-02443-z","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Shotaro Nakajima received Grant-in-Aid for Scientific Research from the Japan Society for the promotion of Science (JSPS) KAKENHI (Grant No. 23K08177). The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research Ethics Committee of Fukushima Medical University (Reference Nos. REC2024-041 and REC2024-152), and all procedures were conducted in accordance with the Declaration of Helsinki. Written informed consent to be included in the study was obtained from all patients.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}